(Breakthrough) Tazbentetol significantly improved symptoms in patients with schizophrenia in a Phase 2 add-on clinical trial, with efficacy sustained for many days after drug discontinuation.

“`html

• Tazbentetol, a new drug under investigation for schizophrenia treatment, showed significant efficacy in a Phase 2 clinical trial. Patients exhibited a reduction of 6.3 points in the PANSS score when using Tazbentetol as an add-on therapy.
• The study reported that even after patients discontinued the medication for six weeks, its therapeutic effects persisted for several days following drug withdrawal. This suggests sustained efficacy and minimal rebound symptoms, which is a promising development for patients managing schizophrenia.

“`